Takeda articles & resources on Made-in-China.com

MHLW Has Approved Takeda Pharmaceutical's NDA of Adcetris 50mg Intended to Treat Patients

Jan 21, 2014

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin ...

Tags: Drug Adcetris, antibody-drug conjugate

Seattle Genetics Has Received Approval of ADCETRIS

Jan 18, 2014

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare ...

Tags: Health, Medicine

Sunesis Pharmaceuticals Has Expanded Its Hematology Franchise

Jan 13, 2014

Sunesis Pharmaceuticals has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec, is for global commercial rights to SNS-062, a ...

Tags: Sunesis Pharmaceuticals, Medicine

Vedolizumab Is Under Review for The Treatment of Adults

Dec 27, 2013

Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food & Drug Administration (FDA) has extended the Prescription Drug User ...

Tags: Takeda Pharmaceutical Company Limited, Prescription Drug User Fee Act

Panasonic India Subsidiary Sets up LED Showroom in Mumbai

Dec 11, 2013

Continuing with its focus on providing the best of innovation and technology, India’s leading electrical solutions manufacturer – Anchor Electricals Pvt. Ltd (A Panasonic Group Company), today opened its first state-of-the-art ...

Tags: LED, Panasonic, showroom

Teva Pharmaceutical Has Licensed Rights to Commercialize Glatiramer Acetate

Dec 9, 2013

Teva Pharmaceutical has licensed rights to commercialize glatiramer acetate to Takeda Pharmaceutical in Japan as part of their agreement signed earlier in 2013. Currently both the firms are working on additional agreements for ...

Tags: Teva Licenses, Medicine

SDP to Increase Production Capacity of Superabsorbent Polymers at Its Chinese Subsidiary

Nov 14, 2013

SDP Global Co., Ltd. ,a consolidated subsidiary of Sanyo Chemical Industries, Ltd. (head office: Higashiyama-ku, Kyoto City; president: Takao Ando) and a joint venture company created between Sanyo Chemical Industries and Toyota Tsusho ...

Tags: SDP, superabsorbent, polymer, manufacturing

National Phase Approvals to Apricus Biosciences's Vitaros

Aug 20, 2013

The Irish Medicines Board and the Netherlands' Medicines Evaluations Board have granted national phase approvals to Apricus Biosciences' Vitaros, indicated to treat patients with erectile dysfunction (ED). Vitaros now has four national ...

Tags: Apricus Bio, Medicine

Japan-Based Takeda Pharma Has Received Positive CHMP Opinion

Jul 30, 2013

Japan-based Takeda Pharma has received positive CHMP opinion for its three new type 2 diabetes therapies from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The therapies include Vipidia ...

Tags: Therapies, CHMP Opinion

Tofacitinib Has Obtained Approval in Several Additional Countries Globally

Jul 17, 2013

Pfizer's rheumatoid arthritis treatment, tofacitinib, has obtained approval in several additional countries globally, including Switzerland, Argentina, Kuwait, UAE and Russia for patients with inadequate response to current therapies. The ...

Tags: Arthritis Drug, International Approvals

Pfizer Has Reached a $2.15bn Settlement with Teva Pharmaceuticals Industries

Jun 14, 2013

Pfizer has reached a $2.15bn settlement with Teva Pharmaceuticals Industries, and Sun Pharmaceutical Industries over Protonix patent-infringement lawsuit in the US. Following 10-years of litigation over the intellectual property for ...

Tags: Pfizer, Sun Pharma

Takeda Has Submitted a Type-II Variation to The EMA for Label Expansion of Rienso

Jun 13, 2013

Takeda Pharmaceutical Company, AMAG Pharmaceuticals' European commercial partner, has submitted a type-II variation to the European Medicines Agency (EMA) for label expansion of Rienso (ferumoxytol). The approval will allow the use of ...

Tags: Takeda, EMA Approval

Takeda Pharmac Will Start Using Bio-Polyethylene Bottles as The Primary Packaging

Jun 7, 2013

Takeda Pharmaceutical Company said it will start using bio-polyethylene bottles (“Bio-PE bottles”) as the primary packaging container for the hypertension treatment product, Azilva. Made from plastic derived from ...

Tags: Takeda Pharma, Packaging, Bottles

Shionogi Has Opted for Qumas ComplianceSP on Microsoft SharePoint 2010

Apr 12, 2013

Japan-based Shionogi has opted for Qumas ComplianceSP on Microsoft SharePoint 2010 to manage and control quality and manufacturing document. Shionogi will use the Qumas technology for users across the clinical and quality assurance areas ...

Tags: Shionogi, Qumas Compliancesp, Quality Content Management

Takeda Has Received a Sanction From The OPMA in Japan

Apr 2, 2013

Takeda has received a sanction from the Osaka Pharmaceutical Manufacturers Association (OPMA) in Japan, for the violation of the pharmaceutical affairs act related to the voluntary recall of Alinamin-F5 Injection in the country in December ...

Tags: Takeda, OPMA, Sanction

Takeda

Related Products